Bioventus Inc
$ 7.62
0.66%
04 Dec - close price
- Market Cap 507,012,000 USD
- Current Price $ 7.62
- High / Low $ 7.64 / 7.47
- Stock P/E 47.31
- Book Value 2.48
- EPS 0.16
- Next Earning Report 2026-03-17
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.06 %
- 52 Week High 11.89
- 52 Week Low 5.81
About
Bioventus Inc. (BVS) is a leading medical device company headquartered in Durham, North Carolina, focused on advancing orthopedic treatments through innovative solutions that bolster the body's natural healing processes. Leveraging cutting-edge technology, Bioventus develops a range of effective products aimed at enhancing pain management and recovery for patients globally. With a strong commitment to improving musculoskeletal care and patient outcomes, Bioventus positions itself as a key player in the health technology sector, offering attractive growth opportunities for institutional investors.
Analyst Target Price
$15.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-06 | 2025-05-05 | 2025-03-10 | 2024-11-05 | 2024-08-06 | 2024-05-07 | 2024-03-12 | 2023-11-07 | 2023-08-08 | 2023-05-16 | 2023-03-31 |
| Reported EPS | 0.15 | 0.21 | -0.0399 | 0.15 | 0.06 | 0.19 | 0.07 | 0.07 | 0.05 | 0.14 | -0.26 | -0.06 |
| Estimated EPS | 0.11 | 0.21 | 0.0228 | 0.085 | 0.03 | 0.07 | -0.07 | 0.02 | -0.02 | 0.03 | -0.15 | 0.05 |
| Surprise | 0.04 | 0 | -0.0627 | 0.065 | 0.03 | 0.12 | 0.14 | 0.05 | 0.07 | 0.11 | -0.11 | -0.11 |
| Surprise Percentage | 36.3636% | 0% | -275% | 76.4706% | 100% | 171.4286% | 200% | 250% | 350% | 366.6667% | -73.3333% | -220% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-17 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.2042 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BVS
2025-11-08 20:46:50
This article provides a detailed financial overview and forecast for Bioventus, Inc. (BVS), including its current stock price, recent performance, key financial metrics, and a compilation of recent news and analyst ratings. It highlights the company's operational segments and its position within the medical technology sector.
2025-11-08 20:46:50
Bioventus Inc. has released its Form 10-Q report for the third quarter of 2025, highlighting stable financial performance with improvements in operating income and a positive net income turnaround. The company's U.S. segment remains the primary revenue driver, particularly in Pain Treatments and Surgical Solutions, which are also targeted for future growth alongside international expansion.
2025-10-12 05:18:11
This article provides a head-to-head comparison of Bioventus (NASDAQ:BVS) and Shoulder Innovations (NYSE:SI), examining their institutional ownership, insider ownership, earnings, valuation, analyst recommendations, and profitability. The analysis concludes that Bioventus outperforms Shoulder Innovations on 7 out of 12 factors discussed. Detailed company profiles are also included.
2024-12-26 21:58:00
Katrina J. Church, SVP and Chief Compliance Officer at Bioventus Inc. (NASDAQ: BVS), sold 2,535 shares of company stock for $26,693 to cover taxes on vested restricted stock units. This transaction occurred after Bioventus saw a 102% gain over the past year and raised its full-year revenue guidance to between $562 million and $567 million due to strong Q3 growth. The company reported a 15% year-over-year increase in Q3 revenue to $139 million, driven by surgical solutions and the HA business.
2024-12-24 00:00:00
A federal judge has approved a $15.25 million settlement in a shareholder lawsuit against Durham-based Bioventus. The lawsuit alleged that the company misled shareholders regarding its financial performance. This settlement concludes the legal claims against the company.
2024-07-19 16:38:00
Bioventus Inc. has agreed to a $15.25 million settlement in a securities class action lawsuit, resolving claims related to rebate practices, financial prospects, and internal controls. While the settlement requires court approval and does not admit liability, it aims to conclude litigation dating back to January 2023. This development occurs as Bioventus reports strong financial performance in Q1 2024 and significant corporate governance changes.
